Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Angiogenic factor with G patch and FHA domains 1 (AGGF1)
- Target
- AGGF1
- Molecular classification
- Splicing factor (general splicing), Angiogenic growth factor, Nuclear/cytoplasmic protein, "Other" (readthrough/novel transcript, non-canonical)
01
Overview
AGGF1 is a multifunctional protein involved in the regulation of alternative splicing, angiogenesis, endothelial cell migration and proliferation, and inflammatory responses. Mutations in AGGF1 are associated with vascular disorders such as Klippel-Trenaunay syndrome, and aberrant expression is linked to poor outcomes in various malignancies. The readthrough transcript combining AGGF1 and ZBED3-AS1 is annotated in genomic databases but is not characterized as a distinct protein, nor is it recognized as a validated therapeutic target in peer-reviewed literature. The functional and clinical relevance is tied to AGGF1 rather than the readthrough form[1][2][4][5][6].
- Other names
- AGGF1Angiogenic factor with G patch and FHA domains 1VFLAGGF1-ZBED3-AS1 readthrough (database/annotation only, not commonly used in literature)
02
Mechanism of action
Anti-angiogenic agents (potential inhibition of AGGF1 function); Modulators of splicing or endothelial signaling (experimental)
03
Biological functions
Alternative splicing regulationAngiogenesis (blood vessel formation)Endothelial cell migration, proliferation, tube formationRegulation of inflammatory response (NF-κB, ERK pathway antagonism)Mesodermal differentiation
04
Disease associations
Vascular/cardiovascular disease (Klippel-Trenaunay syndrome, ischemic injury)Cancer (angiogenesis, tumor growth, poor differentiation, chemoresistance)Inflammatory diseases (anti-inflammatory activity)Sepsis (biomarker for prognosis and classification)
05
Safety considerations
Potential challenges in targeting angiogenesis (risk of abnormal vascular remodeling, impaired wound healing)Potential off-target immune effects due to role in endothelial function and inflammation
06
Interacting drugs
Experimental agents targeting angiogenesis
1 more in the full profile.
07
Biomarkers
Plasma AGGF1 levels for classification and prognosis in sepsis
Beyond the preview
Go deeper on Angiogenic factor with G patch and FHA domains 1 (AGGF1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Angiogenic factor with G patch and FHA domains 1 (AGGF1).